NCT04971746View on ClinicalTrials.gov

Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

May 9, 2022

Study Completion Date

May 9, 2022

Conditions
Healthy
Interventions
DRUG

Pirfenidone

On Days 1 and 13, participants will receive an oral dose of pirfenidone.

DRUG

GLPG4716

From Day 3 to Day 14, participants will receive GLPG4716 daily.

DRUG

Nintedanib

On Days 1 and 13, participants will receive an oral dose of nintedanib.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT04971746 - Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects | Biotech Hunter | Biotech Hunter